Obinutuzumab for the first-line treatment of follicular lymphoma

R Marcus; A Davies; K Ando; W Klapper; S Opat; C Owen; E Phillips; R Sangha; R Schlag; JF Seymour; W Townsend; M Trněný; M Wenger; G Fingerle-Rowson; K Rufibach; T Moore; M Herold; W Hiddemann

Journal article

Obinutuzumab for the first-line treatment of follicular lymphoma

R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, R Sangha, R Schlag, JF Seymour, W Townsend, M Trněný, M Wenger, G Fingerle-Rowson, K Rufibach, T Moore, M Herold, W Hiddemann

New England Journal of Medicine | Published : 2017

DOI: 10.1056/NEJMoa1614598

Abstract

BACKGROUND: Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. METHODS: We randomly assigned patients to undergo induction treatment with obinutuzumab-based chemotherapy or rituximab-based chemotherapy. Patients with a response received maintenance treatment for up to 2 years with the same antibody that they had received in induction. The primary end point was investigator-assessed progression-free survival. RESULTS: A total of..

View full abstract